Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estetrol for vasomotor symptoms in postmenopausal women
NCT04090957Phase 3Completed
- Sponsor
- Estetra SRL
- Start
- Sep 2019
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of estetrol in vasomotor symptoms (4 arms), sponsored by Estetra SRL. Primary endpoints: Mean Change in Weekly Frequency of Moderate to Severe Vasomotor Symptoms From Baseline at 12 weeks and Mean Change in Severity of Moderate to Severe Vasomotor Symptoms From Baseline at 12 weeks. Started Sep 2019; status: completed.
02
Drugs
estetrol
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT04090957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04090957.